Spring til hovednavigation
Spring til søgning
Spring til hovedindhold
Sorter
Keyphrases
Type 2 Diabetes Mellitus (T2DM)
100%
Type 1 Diabetes Mellitus (T1DM)
81%
Type I Diabetes
78%
Diabetes
44%
Chronic Kidney Disease
34%
Type 2 Diabetic Patients
30%
Denmark
30%
Hemoglobin A1c (HbA1c)
28%
Glucagon-like
25%
Placebo
24%
Patients with Diabetes
19%
Meta-analysis
17%
Randomized Controlled Trial
16%
Albuminuria
16%
Cardiovascular Disease
15%
Obesity
15%
95% Confidence Interval
14%
Diabetes Management
14%
Finerenone
14%
1 Receptor
14%
Continuous Glucose Monitoring
14%
Diabetic Kidney Disease
14%
Pre-diabetes (pre-DM)
13%
Older Adults with Diabetes
13%
Estimated Glomerular Filtration Rate
13%
All-cause Mortality
13%
Receptor Agonist
13%
Hypoglycemia
13%
Sodium-glucose Cotransporter 2 Inhibitors (SGLT2i)
12%
Physical Activity
12%
Cardiovascular Mortality
12%
Hazard Ratio
12%
Glycemic Control
12%
Liraglutide
11%
Glucagon
11%
Dapagliflozin
11%
Body Mass Index
10%
Healthcare Professionals
10%
Insulin
10%
Urinary Albumin-to-creatinine Ratio
10%
Cardiovascular Risk Factors
9%
Cardiovascular Outcomes
9%
Randomized Placebo-controlled Trial
9%
Heart Failure
9%
Semaglutide
9%
Weight Loss
8%
Glucose-dependent Insulinotropic Polypeptide
8%
Gestational Diabetes Mellitus
8%
Randomized Clinical Trial
8%
Cardiovascular Events
7%
Kidney
7%
Overweight/obesity
7%
Children with Type 1 Diabetes
7%
Metformin
7%
High Risk
7%
Diabetes Duration
7%
Adolescent Diabetes
7%
Risk Factors
7%
Microalbuminuria
7%
Empagliflozin
6%
Greenland
6%
Glucose-lowering Drugs
6%
Type 2 Diabetes Risk
6%
Genome-wide Association Study
6%
Body Composition
6%
Blood Pressure
6%
Hyperglycemia
6%
Insulin Resistance
6%
Older Adults
6%
Incidence Rate
6%
Living with
6%
Glucagon-like peptide-1 Receptor Agonists (GLP-1 RAs)
6%
Alzheime's Disease
6%
Alzheimer's Disease
6%
Plasma Glucose
5%
Hospitalization
5%
Major Adverse Cardiovascular Events
5%
Insulin Pump
5%
Non-alcoholic Fatty Liver Disease (NAFLD)
5%
COVID-19
5%
Kidney Function
5%
Kidney Disease
5%
Lifestyle Intervention
5%
Without Diabetes
5%
Insulin Sensitivity
5%
Type 2 Diabetes Prevention
5%
Healthy Individuals
5%
Healthy Controls
5%
Kidney Outcomes
5%
Gestational Diabetes
5%
Placebo-controlled
5%
Randomized Trial
5%
During Pregnancy
5%
Automated Insulin Delivery Systems
5%
Medicine and Dentistry
Diabetes
68%
Maturity Onset Diabetes of the Young
66%
Insulin Dependent Diabetes Mellitus
59%
Glucose
30%
Cardiovascular System
29%
Chronic Kidney Disease
27%
Placebo
23%
Insulin
21%
Cardiovascular Disease
19%
Patient with Type 2 Diabetes
18%
Hemoglobin A1c
15%
Cohort Analysis
14%
Hypoglycemia
13%
Finerenone
13%
Glomerular Filtration Rate
12%
Congestive Heart Failure
11%
Randomized Controlled Trial
11%
Body Mass Index
10%
Adolescence
10%
Albuminuria
10%
Diseases
10%
Systematic Review
9%
Albumin
9%
Glycemic
9%
Creatinine
9%
Prevalence
9%
Nephropathy
8%
Glucagon Like Peptide 1
8%
Glucagon-Like Peptide-1 Agonist
8%
Hazard Ratio
8%
Diabetes Mellitus
7%
Physical Activity
7%
Post-Hoc Analysis
7%
Urinary System
7%
Obesity
7%
Kidney Function
7%
Biological Marker
7%
Impaired Glucose Tolerance
6%
Dapagliflozin
6%
Diabetic Nephropathy
6%
Hyperglycemia
6%
Randomized Clinical Trials
6%
Cross Sectional Study
6%
Meta-Analysis
6%
Blood Pressure
6%
Gestational Diabetes
6%
Patient with Type 1 Diabetes
6%
Liraglutide
6%
All Cause Mortality
5%
Gastric Inhibitory Polypeptide
5%
Glycon
5%
Autonomic Neuropathy
5%
Glycemic Control
5%
Cardiovascular Risk
5%
Inflammation
5%
Clinical Trial
5%
Metabolite
5%